Original language | English |
---|---|
Pages (from-to) | 2273-2275 |
Number of pages | 3 |
Journal | Journal of the American College of Cardiology |
Volume | 75 |
Issue number | 17 |
DOIs | |
State | Published - May 5 2020 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of the American College of Cardiology, Vol. 75, No. 17, 05.05.2020, p. 2273-2275.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Circulating Ceramide 16:0 in Heart Failure With Preserved Ejection Fraction
AU - Javaheri, Ali
AU - Allegood, Jeremy C.
AU - Cowart, L. Ashley
AU - Chirinos, Julio A.
N1 - Funding Information: Please note: This study was supported by National Institutes of Health (NIH) grants P30DK056341, R56HL-124073–01A1 (Dr. Chirinos), R01 HL 121510–01A1 (Dr. Chirinos), and 5-R21-AG-043802–02 (Dr. Chirinos), and a VISN-4 research grant from the Department of Veterans Affairs (Dr. Chirinos). Dr. Javaheri is supported by K08HL138262–01; and has been named co-inventor on the patent application for the use of fusion protein nanodiscs for the treatment of heart failure. Dr. Cowart was supported by NIH R01 HL117233 and VA I01 BX00200. Dr. Chirinos has been supported by NIH grants R01-HL 121510–01A1, R61-HL-146390, R01-AG058969, 1R01-HL104106, P01-HL094307, R03-HL146874–01, and R56-HL136730; has received consulting honoraria from Sanifit, Microsoft, Fukuda-Denshi, Bristol-Myers Squibb, OPKO Healthcare, Ironwood Pharmaceuticals, Pfizer, Akros Pharma, Merck, Edwards Lifesciences, Bayer, and JNJ; has received research grants from NIH, Microsoft, Fukuda-Denshi, and Bristol-Myers Squibb; and has been named as inventor in a UPenn patent for the use of inorganic nitrates/nitrites for the treatment of heart failure and preserved ejection fraction, and a patent application for the use of novel neoepitope biomarkers of tissue fibrosis in heart failure. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors acknowledge the Virginia Commonwealth University Lipidomics/Metabolomics Core, the NIH–National Cancer Institute Cancer Center Support Grant P30 CA016059 to the Virginia Commonwealth University Massey Cancer Center, as well as a shared resource grant (S10RR031535) from NIH. Funding Information: Please note: This study was supported by National Institutes of Health (NIH) grants P30DK056341, R56HL-124073?01A1 (Dr. Chirinos), R01 HL 121510?01A1 (Dr. Chirinos), and 5-R21-AG-043802?02 (Dr. Chirinos), and a VISN-4 research grant from the Department of Veterans Affairs (Dr. Chirinos). Dr. Javaheri is supported by K08HL138262?01; and has been named co-inventor on the patent application for the use of fusion protein nanodiscs for the treatment of heart failure. Dr. Cowart was supported by NIH R01 HL117233 and VA I01 BX00200. Dr. Chirinos has been supported by NIH grants R01-HL 121510?01A1, R61-HL-146390, R01-AG058969, 1R01-HL104106, P01-HL094307, R03-HL146874?01, and R56-HL136730; has received consulting honoraria from Sanifit, Microsoft, Fukuda-Denshi, Bristol-Myers Squibb, OPKO Healthcare, Ironwood Pharmaceuticals, Pfizer, Akros Pharma, Merck, Edwards Lifesciences, Bayer, and JNJ; has received research grants from NIH, Microsoft, Fukuda-Denshi, and Bristol-Myers Squibb; and has been named as inventor in a UPenn patent for the use of inorganic nitrates/nitrites for the treatment of heart failure and preserved ejection fraction, and a patent application for the use of novel neoepitope biomarkers of tissue fibrosis in heart failure. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors acknowledge the Virginia Commonwealth University Lipidomics/Metabolomics Core, the NIH?National Cancer Institute Cancer Center Support Grant P30 CA016059 to the Virginia Commonwealth University Massey Cancer Center, as well as a shared resource grant (S10RR031535) from NIH.
PY - 2020/5/5
Y1 - 2020/5/5
UR - http://www.scopus.com/inward/record.url?scp=85083523998&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2020.02.062
DO - 10.1016/j.jacc.2020.02.062
M3 - Letter
C2 - 32354389
AN - SCOPUS:85083523998
SN - 0735-1097
VL - 75
SP - 2273
EP - 2275
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 17
ER -